It's been great to talk to Tom Mackenzie of Bloomberg News about the launch of our protein design model and platform this morning!

Latent Labs@latentlabs.bsky.social · last yr.

Latent-X has been available for over two weeks and we couldn't be more excited about the science already being done with it. Our CEO @saakohl.bsky.social joined @bloomberg.com News Daybreak Europe today to talk why we're building it, and the impact it is having. Watch here: tinyurl.com/yjzyhr23

🧬Latent-X is our first frontier model for protein design. For mini-binders, our AI model achieved picomolar binding affinities — the strongest reported vs prior methods in head-to-head lab validation. Explore our best binders here: platform.latentlabs.com More details on the breakthrough in this🧵

Introducing Latent-X — our all-atom frontier AI model for protein binder design. State-of-the-art lab performance, widely accessible via the Latent Labs Platform. Free tier: platform.latentlabs.com Blog: latentlabs.com/latent-x/ Technical report: tinyurl.com/latent-X

5 months from funding to shipping our first frontier model. Latent-X achieves state-of-the-art hit rates for macrocycles and mini-binders, with picomolar binding affinities — a breakthrough in de novo protein binder design. Available now on our no-code platform!

It's been great to discuss our work with @hannahkuchler.bsky.social & @melissahei.bsky.social at the @financialtimes.com!

Latent Labs@latentlabs.bsky.social · 2y ago

"Simon Kohl, a scientist, has raised $50M to launch a startup to discover new drugs." We’re grateful for the incredible response to our mission. Thank you @financialtimes.com, @hannahkuchler.bsky.social & @melissahei.bsky.social. www.ft.com/content/9214...

Latent Labs comes out of stealth today with $50M funding. Our goal? To push the frontiers of generative biology, giving partners instant access to tools capable of accelerating drug design